Lombard Odier Asset Management Europe Ltd Lowers Position in Regeneron Pharmaceuticals, Inc. $REGN

Lombard Odier Asset Management Europe Ltd decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.9% during the first quarter, HoldingsChannel reports. The firm owned 17,875 shares of the biopharmaceutical company’s stock after selling 3,124 shares during the period. Lombard Odier Asset Management Europe Ltd’s holdings in Regeneron Pharmaceuticals were worth $13,811,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Insigneo Advisory Services LLC raised its stake in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 13 shares in the last quarter. Arjuna Capital boosted its position in Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 14 shares in the last quarter. Guardian Wealth Advisors LLC NC increased its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 14 shares during the period. TD Private Client Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 15 shares during the last quarter. Finally, MCF Advisors LLC boosted its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure – HBSS

Regeneron Pharmaceuticals Stock Performance

REGN opened at $656.01 on Friday. The company has a market cap of $69.35 billion, a P/E ratio of 15.98, a price-to-earnings-growth ratio of 1.45 and a beta of 0.24. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average price is $635.78 and its 200-day moving average price is $714.44. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period last year, the business earned $8.22 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on REGN. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $787.88.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.